Novavax’s COVID-19 Vaccine May Be Authorized Next

There is news that Novavax’s maybe the next COVID emergency vaccine to be authorized in the USA.

The company plans to file the paperwork in the coming weeks and can beat out other coming vaccinations.

Public health officials and researchers expect that the Novavax shot will fill in supply gaps in the U.S. and worldwide as the people reported side effects with Johnson & Johnson.

Lawrence Gostin, a global health law professor at Georgetown University, told Politico, “ The Johnson & Johnson vaccine has taken a reputational hit, and people are more hesitant to take it. I think Novavax is going to be a reasonably significant player.”

The company has pledged to deliver 100 million doses to the U.S. this year. The company has partnered with production companies worldwide, including factories in Italy, Japan, India, Czech Republic,  Japan, and South Korea — to create vaccine batches.

According to Reuters, “ Novavax plans to produce 150 million doses per month by the second half of the year.”

The Serum Institute in India will produce more than 1 billion doses of the Novavax shot this year. This batch of vaccination will be distributed to the global vaccine effort.

According to CNBC,” The institute will likely seek authorization for the vaccine in India once the FDA authorizes the shot in the U.S., which could occur in May.”

Politico reported that the U.S. hasn’t factored the Covavax shot into the COVID-19 response plan yet. Though the vaccine was entered late for trials, the March clinical trials show that the vaccine has an efficacy rate similar to other candidates – Pfizer and Moderna.

According to the researchers, “ The Novavax vaccine was about 55% effective against COVID B.1.351 variant during Interim clinical trials.”

More data about variants will be shared during the release of Novavax files for FDA authorization. The researchers also say that the Novavax shot could be used as a booster shot in the coming years.

Gregory Glenn, the president of research and development for Novavax, told Politico, “Everyone will need to be boosted. ”

 “This is a viral respiratory disease, and we know from the flu that immunity from an infection is good for maybe 12 months, maybe 18 months,” he said. “After that, people become susceptible again. After that, we’re going to have to boost.”

Want to know more about COVD-19 vaccinations, stay tuned to the WiseRx Discount Card blog!